logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Gilteritinib tops salvage chemotherapy for FLT3+ relapsed/refractory AML

ADMIRAL study shows survival benefit across major ITD3 comutations.